Clinicopathological significance and underlying molecular mechanism of downregulation of basonuclin 1 expression in ovarian carcinoma. Issue 2 (January 2022)

• Record Type: Journal Article
• Authors: Liang, Zi-Qian; Zhong, Lu-Yang; Li, Jie; Shen, Jin-Hai; Tu, Xin-Yue; Zhong, Zheng-Hong; Zeng, Jing-Jing; Chen, Jun-Hong; Wei, Zhu-Xin; Dang, Yi-Wu; Huang, Su-Ning; Chen, Gang
• Is Part Of: Experimental biology and medicine. Volume 247:Issue 2(2022)
• Page Start: 106
• Page End: 119
• Publication Date: 2022-01
• Subjects: Basonuclin 1 -- ovarian carcinoma -- tumorigenesis -- prognosis; Physiology -- Periodicals; Biology, Experimental -- Periodicals; Medicine, Experimental -- Periodicals; 610.72
• DOI: 10.1177/15353702211052036
• Languages: English
• ISSNs: 1535-3702

Abstract

In this study, we aim to identify the clinical significance of basonuclin 1 ( BNC1 ) expression in ovarian carcinoma (OV) and to explore its latent mechanisms. Via integrating in-house tissue microarrays, gene chips, and RNA-sequencing data, we explored the expression and clinical value of BNC1 in OV. Immunohistochemical staining was utilized to confirm the protein expression status of BNC1. A combined SMD of –2.339 (95% CI : –3.649 to –1.028, P < 0.001) identified that BNC1 was downregulated based on 1346 samples, and the sROC (AUC = 0.93) showed a favorable discriminatory ability of BNC1 in OV patients. We used univariate and multivariate Cox regulation to evaluate the prognostic role of BNC1 for OV patients, and a combined hazard ratio of 0.717 (95% CI : 0.445–0.989, P < 0.001) revealed that BNC1 was a protective factor for OV. Furthermore, the fraction of infiltrating naive B cells, memory B cells, and other immune cells showed statistical differences between the high- and low- BNC1 expression groups through cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm. Enrichment analysis showed that BNC1 may have a relationship with immune-related items in OV. By predicting the potential regulatory transcription factors (TFs) of BNC1, friend leukemia virus integration 1 ( FLI1 ) may be a potential upstream TF of BNC1 . Corporately, a decreasing trend of BNC1 may serve as a tumor suppressor and prognostic biomarker in OV patients. Moreover, BNC1 may take part in immune-related pathways and influence the fraction of tumor-infiltrating immune cells.